BioAtla, Inc. Common Stock (BCAB) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAB trades at $3.44 with a market cap of $6.50M and a P/E ratio of -0.73. BCAB moved -3.36% today. Year to date, BCAB is -82.97%; over the trailing twelve months it is -81.51%. Its 52-week range spans $3.26 to $126.25. Rallies surfaces BCAB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
BioAtla Plans 50-for-1 Share Consolidation and Reports $9.8M Loss: BioAtla will enact a 50-for-1 share consolidation on April 6 to regain Nasdaq’s $1 minimum bid requirement and adopt CUSIP 09077B203. The company posted Q4 R&D expenses of $8 million, a $9.8 million net loss, and $7.1 million cash, launching a strategic review and asset monetization process.
| Metric | Value |
|---|---|
| Price | $3.44 |
| Market Cap | $6.50M |
| P/E Ratio | -0.73 |
| EPS | $-4.97 |
| Dividend Yield | 0.00% |
| 52-Week High | $126.25 |
| 52-Week Low | $3.26 |
| Volume | 20 |
| Avg Volume | 0 |
| Revenue (TTM) | $2.00M |
| Net Income | $-50.62M |
| Gross Margin | 0.00% |
BCAB analyst coverage data. Average price target: $0.00.